• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23368 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure - Addendum to commission H20-06]
2021     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating juvenile idiopathic arthritis. NICE technology appraisal guidance 735
2021     Ontario Health Proton Beam Therapy for Cancer in Children and Adults: A Health Technology Assessment
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: submission of surgical specimens to the anatomic pathology laboratory - relevance and indications - orthopedic surgery and neurosurgery]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Coronary lithoplasty for coronary heart disease - Addendum to commission H20-07]
2021     National Institute for Health and Care Excellence (NICE) Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. NICE technology appraisal guidance 736
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of the SpaceOAR hydrogel rectal spacer during prostate radiotherapy]
2021     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: mandatory vaccination
2021     Health Technology Wales (HTW) Handheld single lead electrocardiogram devices to detect atrial fibrillation in older adults and those with intermittent episodes
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Addendum to commission H20-08]
2021     National Institute for Health and Care Excellence (NICE) Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer. NICE technology appraisal guidance 737
2021     Ontario Health Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure
2021     Health Technology Wales (HTW) Point-of-care ultrasound to diagnose gallstone disease
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (psoriatic arthritis) - Addendum to Commission A21-15]
2021     National Institute for Health and Care Excellence (NICE) Berotralstat for preventing recurrent attacks of hereditary angioedema. NICE technology appraisal guidance 738
2021     Ontario Health Vaginal pessaries for pelvic organ prolapse and stress urinary incontinence
2021     Scottish Medicines Consortium (SMC) Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) - Addendum to Commission A21-08]
2021     National Institute for Health and Care Excellence (NICE) Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable. NICE technology appraisal guidance 739
2021     Scottish Medicines Consortium (SMC) Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Levofloxacin/dexamethasone (inflammation and infection associated with cataract surgery) - Addendum to Commission A21-12]
2021     National Institute for Health and Care Excellence (NICE) Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 740
2021     Scottish Medicines Consortium (SMC) Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
2021     Health Technology Wales (HTW) Natriuretic peptides to rule-in and rule-out a diagnosis of acute heart failure in adults in the emergency department setting
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for updating the DMP "Asthma"]
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) National spending and uptake of mobile radiology services in aged care facilities: an opportunity to improve access remains
2021     National Institute for Health and Care Excellence (NICE) Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 741
2021     Penn Medicine Center for Evidence-based Practice (CEP) Ambulatory antibiotic prophylaxis for skin procedures
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Selpercatinib for treating advanced thyroid cancer with RET alterations. NICE technology appraisal guidance 742
2020     Technology Assessment at SickKids (TASK) Microcosting of whole genome sequencing (WGS) of trios in heterogeneous pediatric cardiac population
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: prophylactic use of hydroxychloroquine (HCQ)
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biomarker-based tests to support the decision for or against adjuvant systemic chemotherapy in primary breast cancer - state of knowledge]
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: treatment with hydroxychloroquine (HCQ)
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gilteritinib (AML) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: infectivity of patients who have recovered from disease
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020     Penn Medicine Center for Evidence-based Practice (CEP) Cytokine adsorption for treatment of COVID-19 disease
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neratinib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: decontamination and reprocessing of personal protective equipment (PPE)
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (combination with axitinib, renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020     Penn Medicine Center for Evidence-based Practice (CEP) Transmission of respiratory infections via showers
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (head and neck squamous cell carcinoma, monotherapy) - Benefit assessment according to §35a Social Code Book V]
2020     NIHR Health Technology Assessment programme Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial
2020     Penn Medicine Center for Evidence-based Practice (CEP) Remdesivir for treatment of COVID-19 disease
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (head and neck squamous cell carcinoma, combination therapy) - Benefit assessment according to §35a Social Code Book V]
2020     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment of depression with transcranial magnetic stimulation using an H-coil (dTMS)
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: sedation-ventilation liberation of COVID+ patients
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Hyperbaric oxygenotherapy for fybromialga, peripheral vascular disease, neurological disease and other indications]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V]
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: surgical masks and filtering face piece respirators (FFR) for health care providers
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Effectiveness and safety of endovascular treatment with venous adhesive in varicose veins of the lower extremities]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Newborn screening for spinal muscular atrophy (SMA)]
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: point-of-care (POC) testing
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Analysis of the efficacy and safety of robotic spinal surgery]
2020     Adelaide Health Technology Assessment (AHTA) Genetic testing for diagnosis of inheritable cardiac rhythm disorders
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 6 to < 12 months, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anxiety disorders: does the complementary use of eye movement desensitization and reprocessing (EMDR) therapy as a psychotherapeutic approach lead to better results?]
2020     NIHR Health Technology Assessment programme Best-practice prevention alone or with conventional or biological caries management for 3- to 7-year-olds: the FiCTION three-arm RCT
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: antibiotic management in ambulatory patients
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Clinical effectiveness of pulse oximetry for neonatal screening of critical congenital heart diseases]
2020     Adelaide Health Technology Assessment (AHTA) Detection of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibody (MOG) antibodies for diagnosis of neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein antibody-related demyelination (MARD)
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (breast cancer) - Addendum to Commission A19-81]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Testicular cancer: does regular screening for men from the age of 16 lead to better treatment outcomes?]
2020     NIHR Health Technology Assessment programme Total versus partial knee replacement in patients with medial compartment knee osteoarthritis: the TOPKAT RCT
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: temperature screening for healthcare personnel
2020     Andalusian Health Technology Assessment Area (AETSA) [C-Reactive Protein point-of-care testing (CRP-POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections]
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Hypoglossal nerve stimulation systems for treatment of obstructive sleep apnea]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (small cell lung cancer) - Addendum to Commission A19-86]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cervical spine syndrome: the impact of the duration and frequency of physiotherapy on treatment success]
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: criteria for discharging patients from inpatient care
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90]
2020     Norwegian Institute of Public Health (NIPH) Safety, clinical effectiveness, predictive accuracy and cost effectiveness of blood based tests for women with suspected preeclampsia: a health technology assessment
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: high flow nasal cannula (HFNC)/non-invasive positive pressure ventilation (NIPPV) indications
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Addendum to Commission A19-80]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Seasonal affective disorder: do non-drug interventions such as light and vitamin therapy lead to better results?]
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: proning considerations for patients on HFNC or BIPAP
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib (ovarian cancer) - Addendum to Commission A19-88]
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: criteria for advising home care patients to return to the hospital
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asfotase alfa (hypophosphatasia) - Addendum to Commission A19-89]
2020     NIHR Health Services and Delivery Research programme Stroke Sentinel Audit Programme: Investigating and Evaluating Stroke Therapy (SSNAPIEST)
2020     Norwegian Institute of Public Health (NIPH) Intracoronary lithotripsy for the treatment of coronary artery disease: a health technology assessment
2020     Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: surge triage for suspected influenza-like illness
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the DMP "COPD"]
2020     NIHR Health Services and Delivery Research programme An evaluation of a multifaceted intervention to reduce antimicrobial prescribing in care home residents [REducing Antimicrobials in Care Homes (REACH)]: a non-randomised feasibility study and process evaluation
2020     Norwegian Institute of Public Health (NIPH) Disease modifying drugs for treatment of primary progressive multiple sclerosis: A health technology assessment
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab emtansine (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020     HTA South [Exercise test in the investigation of suspected chronic coronary syndrome: a comparison with imaging and other functional tests]
2020     NIHR Health Services and Delivery Research programme UK Study of tendon Achilles Rehabilitation multicentre randomised clinical trial (UK STAR)
2020     Scottish Health Technologies Group (SHTG) The Scottish asynchronous digital dermatology appointment service (DDAS)
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (renal cell carcinoma) - Addendum to Commission A19-95]
2020     HTA South [The use of hydrogel spacer in radiotherapy of prostate cancer]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use guide: pharmacological treatment of sexually transmitted and blood-borne infections ─ infections caused by chlamydia trachomatis and neisseria gonorrhoeae]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (renal cell carcinoma) - Addendum to Commission A19-95]
2020     NIHR Health Technology Assessment programme Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neratinib (breast cancer) - Addendum to Commission A19-98]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for kidney transplantations - Rapid report]
2020     Canadian Agency for Drugs and Technologies in Health (CADTH) Condition-level review on tuberculosis: repository of evidence and resources
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Prostate cancer screening with the PSA test]
2020     NIHR Health Services and Delivery Research programme IMPlementation of A Relatives Toolkit (IMPART study): examining the critical success factors, barriers and facilitators to implementation of an online supported self-management intervention in the NHS